Global NICU Genetic Testing Market Size Likely to Grow at a CAGR of 10.67% By 2035

Market Size and Growth

As per the NICU genetic testing market size analysis conducted by the CMI team, the NICU genetic testing market is expected to record a CAGR of 10.67% from 2026 to 2035. In 2026, the market size was USD 1.74 Billion. By 2035, the valuation is anticipated to reach USD 4.33 Billion.

NICU Genetic Testing Market Revenue and Trends

The NICU genetic testing market is poised to grow on a staggering note between 2026 and 2035 owing to faster adoption of rWGS (rapid whole-genome sequencing) as one of the first-line diagnostics in the high-income regions along with expansion of compulsory newborn screening panels in the emerging markets. Also, switching to cloud-native bioinformatics and AI-driven interpretation is expediting the growth by curtailing the time of diagnosis, especially for the critically ill neonates aged 48 hours up to a few weeks.

What are the Factors That Have a Significant Contribution to the Growth of the NICU Genetic Testing Market?

The NICU genetic testing market is expected to witness tremendous growth due to the rising prevalence of genetic disorders such as Down syndrome and chromosomal abnormalities owing to rising maternal age (above 35 years), which is likely to bolster further the growth of genetic disorder diagnosis in the NICU. Additionally, rapid Whole-Genome Sequencing tests being an effective tool in diagnosing the chromosomal mutations and genetic disorders in the unborn or newborn babies in order to avert the chances of further complications in the diagnosed babies are expected to spur the growth of the NICU genetic testing market. These genetic tests that provide the information about the genetic structure of the unborn or newborn are widely screened in terms of diagnosing and enabling the babies with speedy treatment and timely cures.

The availability of government initiatives to support the implementation of rapid whole-genome sequencing, favorable reimbursement policies to ensure accelerated diagnosis, and escalation of growth opportunities for diagnostics service provider enterprises are some of the factors expected to drive the overall NICU genetic testing market in the near future. For instance, The U.K. National Health Services (NHS) announced the genetic testing program under the 100,000 Genomes Program across U.K. regions for the patients with diagnosed genetic disorders. Whole genome sequencing is performed by this Genetic testing Support Services offered through the UK NHS Genomic Medicine Service. Similarly, government mandates newborn screening tests in several states in the U.S. to aid diagnosis and prevention of the severity of congenital disorders, which is likely to influence the NICU genetic testing market positively. Moreover, integration of Next-generation Sequencing (NGS) in precision medicine is likely to create further growth opportunities for the NICU genetic testing market over the coming years.

Segment Insights

By Product & Service

The global market for consumables and reagents is anticipated to hold the dominant share. Consumables and reagents are an indispensable element in diagnostic runs, as many tests are performed in tandem for precise results. Increasing global test volume is expected to steadily contribute toward revenue generation for consumables and reagents manufacturers. Software and services are expected to witness the fastest growth over the analysis period. This is attributed to the evolving paradigm in data management as well as the shift from data generation to data interpretation.

The demand for AI-driven bioinformatics to manage data is expected to drive the growth of the software segment. The need for genetic counseling services to guide patients on how to best use their genetic testing results is anticipated to bode well for the growth of the services segment. The need for software and services is increasing along with the rising demand for translating complex datasets into clinical decisions.

The global diagnostic sector is growing rapidly, and this evolution is expected to continue over the next few years. The rise of larger datasets as well as the need for evolving analytical tools to translate information into valuable data is expected to fuel the need for bioinformatics across the globe. This demand for bioinformatics is expected to provide lucrative growth avenues in the services and software segment of the global diagnostic market. Moreover, the rising need for clinical decision support systems to generate analytical reports and remote diagnostic imaging is anticipated to augment the growth of the software segment throughout the analysis period.

By Test Type

The present scenario is such that parents of newborns with unexplained medical symptoms can make a smart decision with an option for Rapid Whole-Genome Sequencing (rWGS) upfront instead of waiting for long diagnostic tests. Top-of-the-line technology is used, and for the same, it requires universal government funding with no additional costs to the parents. However, one could expect to see rWGS and Exome Sequencing transitioning to first-line standards like the newborn screening panels are today. The fact that there are 10-15% of NICU infants with unexplained symptoms is keeping the cash registers ringing for the NICU genetic testing market. Additionally, the length of stay and costs associated with a stay at the NICU are reduced with rWGS test results delivered and actionable insights provided to the clinician in under 48 hours.

By Technology

Next-generation sequencing (NGS) is the gold standard for diagnosing neonates suffering from rare genetic disorders. Its rapid whole-genome sequencing (rWGS) is capable of diagnosing neonates with a record efficacy of less than 48 hours. In addition, the systems involve reliable sequencing of DNA and subsequent interpretation of sequence variants. Tandem Mass Spectrometry GMT is the fastest-growing segment in terms of CAGR. Growing number of newborn screening (NBS) programs across both – developed and developing nations is a significant factor driving the growth of the segment. With the rapidly transforming healthcare landscape, developing nations in Asia and Africa are now transitioning toward advanced screens while making it mandatory for newborns to test for up to 50 genetic disorders. Demand for tandem mass spectrometry is surging as they can assist in preventive health by early diagnosis and treatment.

By End-user

The hospital and NICU segments are anticipated to dominate the NICU genetic testing market. This is credited to the fact that hospitals and NICUs are always at the forefront of critical care for improving the prognosis of patients, which requires rapid whole-genome sequencing for neonates so that diseases can be detected early and action can be taken as early as possible. The specialty clinics segment is predicted to witness the fastest CAGR due to the rising number of genetic counseling clinics whose aim is to talk to the parent about the probability of a disease in their newborn and seek a roadmap regarding the long-term management of the child with the disease even though it may take years to detect it and also post-acute follow-up. The segment is anticipated to continue to grow due to the presence of advanced genomic testing laboratories in specialized genetic counseling clinics, which offer a cost-effective alternative to hospitals or NICUs while providing many reliable tests such as non-invasive prenatal testing (NIPT), carrier testing, and preimplantation and prenatal genetic diagnosis. The abundance of decentralized, cloud-based informatics solutions to interpret genomic data also drives the segment.

Regional Insights

North America dominates the NICU genetic testing market due to the presence of advanced healthcare infrastructure, high awareness of personalized medicine, incorporation of rapid whole-genome sequencing (rWGS), and a robust reimbursement framework in the region. The Asia Pacific is expected to witness the fastest CAGR during the forecast period owing to the massive birth pool and increasing healthcare expenditure in economies such as China and India. Moreover, various government initiatives taken for reducing infant mortality, including mandatory screening programs and the integration of genomics into neonatal care, are bound to create ample opportunities for the growth of the NICU genetic testing market. The rise in the awareness of global neonatal care has also increased the use of genetic testing.

Report Scope

Recent Developments

• In November 2024, Myriad Genetics, Inc. introduced Sneak Peek. It comes across as an at-home gender test and is available in 8800 retail shops all over the U.S.

List of the prominent players in the NICU Genetic Testing Market:

• Illumina Inc.
• Thermo Fisher Scientific
• Revvity (erstwhile PerkinElmer)
• Agilent Technologies
• Others

The NICU Genetic Testing Market is segmented as follows:

By Product & Service

• Consumables & Reagents
• Instruments
• Software/Services

By Test Type

• Newborn Screening Panels/Tests
• Diagnostic Techniques
  • Rapid Whole-Genome Sequencing (rWGS)
  • Exome Sequencing
• Others
  • cCGH
  • FISH
  • PCR

By Technology

• Next-Generation Sequencing (NGS)
• Tandem Mass Spectrometry

By End-user

• Hospitals & NICUs
• Specialty Clinics
• Diagnostic Laboratories

Regional Coverage:

North America

• U.S.
• Canada
• Mexico
• Rest of North America

Europe

• Germany
• France
• U.K.
• Russia
• Italy
• Spain
• Netherlands
• Rest of Europe

Asia Pacific

• China
• Japan
• India
• New Zealand
• Australia
• South Korea
• Taiwan
• Rest of Asia Pacific

The Middle East & Africa

• Saudi Arabia
• UAE
• Egypt
• Kuwait
• South Africa
• Rest of the Middle East & Africa

Latin America

• Brazil
• Argentina
• Rest of Latin America